Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M70,743Revenue (TTM) $M15,067Net Margin (%)79.2Altman Z-Score1.0
Enterprise Value $M100,792EPS (TTM) $29.1Operating Margin %-19.7Piotroski F-Score8
P/E(ttm)7.3Beneish M-Score-1.9Pre-tax Margin (%)-40.1Higher ROA y-yY
Price/Book1.010-y EBITDA Growth Rate %--Quick Ratio1.1Cash flow > EarningsN
Price/Sales5.05-y EBITDA Growth Rate %3.6Current Ratio1.2Lower Leverage y-yY
Price/Free Cash Flow157y-y EBITDA Growth Rate %-49.1ROA % (ttm)9.1Higher Current Ratio y-yY
Dividend Yield %1.0PEG--ROE % (ttm)14.8Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M334ROIC % (ttm)-1.5Gross Margin Increase y-yY

Gurus Latest Trades with AGN

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

AGN is held by these investors:



AGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
SAUNDERS BRENT LChairman, President and CEO 2017-06-16Buy86$239.04-11.48view
Basgoz NesliDirector 2017-05-18Sell1,889$220.45-4.01view
BISARO PAULDirector 2017-03-02Sell70,000$246.68-14.22view
Basgoz NesliDirector 2016-12-08Sell500$188.7212.13view
SAUNDERS BRENT LCEO and President 2016-11-21Buy5,250$189.1311.89view
Hilado Maria TeresaCFO 2016-11-11Buy1,422$210.640.46view
Basgoz NesliDirector 2016-08-05Sell758$253.02-16.37view
Hilado Maria TeresaCFO 2016-06-02Buy661$241.57-12.4view
Basgoz NesliDirector 2016-05-11Sell459$225.1-5.99view
Basgoz NesliDirector 2015-12-07Sell2,300$312.96-32.38view

Press Releases about AGN :

Quarterly/Annual Reports about AGN:

News about AGN:

Articles On GuruFocus.com
Allergan Receives Refusal to File Letter from FDA for Vraylar® (cariprazine) Supplemental New Drug Sep 22 2017 
New Data from CENTAUR Phase 2b Clinical Study Supports Continued Development of Cenicriviroc (CVC) i Sep 22 2017 
Allergan Innovation Recognized With Three 2017 Allure Best of Beauty Breakthrough Awards Sep 19 2017 
FDA Approves Amgen And Allergan's MVASI™ (bevacizumab-awwb) For The Treatment Of Five Types Of Can Sep 14 2017 
Allergan Launches New Brilliant Distinctions® Patient Loyalty Program Sep 12 2017 
The Allergan Foundation to Donate $150,000 to Support Hurricane Irma Relief Efforts Sep 11 2017 
Amgen And Allergan Present Phase 3 Data On Biosimilar Trastuzumab Candidate ABP 980 At The European Sep 09 2017 
Wallace Weitz's 7 Largest Sales of the 2nd Quarter Sep 08 2017 
Allergan and Saint Regis Mohawk Tribe Announce Agreements Regarding RESTASIS® Patents Sep 08 2017 
Allergan to Present New Data on Chronic Migraine at the International Headache Congress in Vancouver Sep 06 2017 

More From Other Websites
No related articles found.

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}